Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Gaming; DHCoE On AI; Hello Heart

In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app. Stories discussed in this episode: MindMaze, ‘A Ratio Of Luke Skywalker And R2-D2’, Navigates The DTx Galaxy Click Therapeutics Anticipates Pharma Will Begin Developing Digital Drugs From Clinical Stage Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’ DHCoE-AI-Lifecycle-Management-Plan-To-Serve-As-Playbook-For-Standards Hello Heart Says Update To Cardiovascular Health Tracker Could Benefit Women Especially